Oslo, 4 August 2022 - Navamedic has signed an agreement with the French
pharmaceutical company Vectans Pharma, which gives Navamedic the exclusive right
to market and sell an innovative and unique muco-adhesive buccal tablet for
single-dose treatment of cold sores (herpes labialis) in the Nordic and Benelux
regions. This entitles Navamedic to the ownership of the marketing
authorizations for the product in these regions.

"This acquisition is a great example of how we can utilize our strong presence
and in-depth competence in our markets to broaden our portfolio through
partnerships with international pharma companies and introduce attractive
products to the benefit of end-users. It is a key element of our value creation
strategy to secure and increase value creation through ownership of products and
exclusive marketing rights," says Kathrine Gamborg Andreassen, CEO of Navamedic
ASA.

The product is currently marketed as a prescription drug in the US and South
Korea but is now in transition to becoming a non-prescription or "Over the
Counter (OTC)" drug in many markets. It has already been approved as OTC drug in
France and Italy and applications are currently in progress in many European
countries.

Cold sores - also called fever blisters - is a common and recurring condition
that affects about 20 - 40% of the population. It is caused by the herpes
simplex virus and the outbreaks are often triggered by another illness, sunshine
exposure, or menstrual periods. During outbreaks, the sores are contagious from
the first moment of tingling and can spread from person to person by close
contact.

The transfer of the marketing authorizations will take place subsequent to the
OTC approval in each country. Navamedic expects the first commercial sale in the
Nordics and Benelux to take place in the first half of 2024.

"We are delighted to collaborate with Navamedic and to initiate our partnership
together. We firmly believe that Sitavig® has the potential to become the 'best
-in-disease' medicine for cold sores in the Nordic and Benelux regions, offering
a new innovative treatment to patients in need. This partnership is an important
step in our development plan and reinforces our international strategy", says
Jérôme Théron, co-founder and CEO of Vectans Pharma".

About Sitavig®:

Sitavig® (acyclovir) is a 50mg Muco-Adhesive Buccal tablet that represents a
breakthrough in the treatment of cold sores. Sitavig® is a unique single-dose
treatment that is placed under the patient's lip and works by delivering a
concentrated dose of acyclovir that stays localized at the site of viral
replication in the mouth.

For further information, please contact:

Kathrine Gamborg Andreassen, CEO, Navamedic

Mobile: +47 951 78680

E-mail: kathrine@navamedic.com

Lars Hjarrand, CFO, Navamedic

Mobile: +47 917 62842

E-mail: lars.hjarrand@navamedic.com

About Navamedic ASA:

Navamedic ASA is a Nordic pharma company and reliable provider of high-quality
products, delivered to hospitals and through pharmacies, meeting the specific
needs of patients and consumers by leveraging its highly scalable market access
platform, leading category competence and local knowledge. Navamedic is present
in all the Nordic countries, the Baltics and Benelux, with sales representation
in the UK and Greece. Navamedic is headquartered in Oslo, Norway, and listed on
the Oslo Stock Exchange (ticker: NAVA).

For more information, please visit www.navamedic.com

About Vectans Pharma:

"Vectans Pharma is a French pharmaceutical company with an international reach,
specialized in the development of muco-adhesive drugs, and offering new
therapeutic perspectives to the pharmaceutical industry. Thanks to its
innovative platform, Lauriad®, our company ensures the development of new drugs
and, with its international partners, the commercialization of Sitavig® and
Loramyc® worldwide. Vectans Pharma delivers life-changing treatments, respectful
of both humans and the environment, that improve patient access and experience
around the world."

For more information about Vectans Pharma, please visit
https://www.vectanspharma.com/ (https://eur02.safelinks.protection.outlook.com/?
u
rl=https%3A%2F%2Fwww.vectanspharma.com%2F&data=05%7C01%7Cole.henrik.eriksen%40na
v
amedic.com%7C5aa1f243cc50477aa6cd08da643104cf%7Ca5635f8e246b48e094e8806923fb2a69
%
7C1%7C0%7C637932458953341715%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjo
i
V2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=rj2ytK6psxj5vj10b%2
B
nokixJS5uClOtg1Q%2FU%2Fpt4Rp0%3D&reserved=0)